Premium
Partial‐ and full‐mouth scaling and root planing in type 2 diabetic subjects: a 12‐mo follow‐up of clinical parameters and levels of cytokines and osteoclastogenesis‐related factors
Author(s) -
Santos V. R.,
Ribeiro F. V.,
Lima J. A.,
Miranda T. S.,
Feres M.,
Bastos M. F.,
Duarte P. M.
Publication year - 2012
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/j.1600-0765.2011.01403.x
Subject(s) - scaling and root planing , medicine , osteoprotegerin , periodontitis , chronic periodontitis , tumor necrosis factor alpha , gastroenterology , activator (genetics) , cytokine , dentistry , receptor , endocrinology
Santos VR, Ribeiro FV, Lima JA, Miranda TS, Feres M, Bastos MF, Duarte PM. Partial‐ and full‐mouth scaling and root planing in type 2 diabetic subjects: a 12‐mo follow‐up of clinical parameters and levels of cytokines and osteoclastogenesis‐related factors. J Periodont Res 2012; 47: 45–54. © 2011 John Wiley & Sons A/S Background and Objective: The aim of this study was to evaluate the effects of full‐mouth scaling and root planing (FMSRP) and partial‐mouth scaling and root planing (PMSRP), up to 12 mo after treatment, on clinical parameters, and levels of cytokines and osteoclastogenesis‐related factors in type 2 diabetic subjects with chronic periodontitis. Material and Methods: Thirty‐four subjects received FMSRP ( n = 17) or PMSRP ( n = 17) within 24 h or in multiple sessions, respectively. Clinical parameters and local levels of tumor necrosis factor‐α (TNF‐α), interferon‐γ (IFN‐γ), interleukin (IL)‐17, IL‐23, IL‐4, receptor activator of NF‐β ligand and osteoprotegerin were assessed at baseline, and 3, 6 and 12 mo after therapies. Results: Clinical parameters improved after both therapies ( p < 0.05), and no between‐group differences were observed at any time‐point ( p > 0.05). Overall, there were no considerable differences in the local levels of the biomarkers studied between groups ( p > 0.05). The IL‐23 concentration and total amount of IFN‐γ increased in the FMSRP group and decreased in the PMSRP group from baseline to 3 mo and from baseline to 6 mo, respectively ( p < 0.05). Conclusion: Both PMSRP and FMSRP promoted benefits in clinical parameters and showed a similar modulation of cytokines and osteoclastogenesis‐related factors at 12 mo in type 2 diabetic subjects.